Patents Issued in April 30, 2024
  • Ethyl-2[9-2(2-hydroxyquinolin-3-yl)-1,8-dioxo-3,4,9,10-tetrahydroacridine-10-yl]-acetate as an antimicrobial compound
    Patent number: 11970454
    Abstract: An ethyl 2-[9-(2-hydroxyquinolin-3-yl)-1,8-dioxo-3,4,9,10-tetrahydroacridine-10-yl]-acetate compound, its synthesis, and its use as an antimicrobial agent.
    Type: Grant
    Filed: November 2, 2023
    Date of Patent: April 30, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Hany Mohamed Abd El-Lateef Ahmed, Mai Mostafa Khalaf Ali, Antar Ahmed Abdelhamid Ahmed
  • 7-(4-fluorobenzylidene)-4-(4-fluorophenyl)-2-methoxy-6,7-dihydro-5H-cyclopenta[b]pyridine-3-carbonitrile as an antimicrobial compound
    Patent number: 11970455
    Abstract: A 7-(4-fluorobenzylidene)-4-(4-fluorophenyl)-2-methoxy-6,7-dihydro-5H-cyclopenta[b]pyridine-3-carbonitrile compound, its synthesis, and its use as an antimicrobial agent.
    Type: Grant
    Filed: December 8, 2023
    Date of Patent: April 30, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Mohamed Gouda Mahmoud, Hany Mohamed Abd El-Latef Ahmed, Mai Mostafa Khalaf Ali, Saad Shaaban, Antar Ahmed Abdelhamid Ahmed
  • Synthesis of thiosemicarbazide analogue as inhibitor of tyrosinase, skin hyperpigmentation, and fruit and/or vegetable browning
    Patent number: 11970456
    Abstract: A 2-((1H-indazol-5-yl)methylene)hydrazinecarbothioamide compound, its synthesis, and its use as a tyrosine kinase inhibitor. In particular, the synthesis of the 2-((1H-indazol-5-yl)methylene)hydrazinecarbothioamide compound as shown below. This compound has a high efficacy of inhibiting mushroom tyrosinase enzyme, and is a potent inhibitor of tyrosinase that can be used as an inhibitor of skin hyperpigmentation as well as an inhibitor of fruit and vegetable browning.
    Type: Grant
    Filed: September 21, 2023
    Date of Patent: April 30, 2024
    Assignee: KING SAUD UNIVERSITY
    Inventors: Ahmed Muhammad Bari, Usman Ghani
  • Metabolites of [3-(4-(2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1H-imidazol-4-yl)-phenoxy)-propyl]-diethyl-amine
    Patent number: 11970457
    Abstract: The present invention relates to metabolites of [3-(4-{2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1H-imidazol-4-yl}-phenoxy)-propyl]-diethyl-amine. These metabolites may act as RAGE antagonists. These metabolites may also be useful in assays to measure the presence or amount of one or more metabolites of the parent compound in a sample.
    Type: Grant
    Filed: October 27, 2022
    Date of Patent: April 30, 2024
    Assignee: VTV THERAPEUTICS LLC
    Inventors: William Kenneth Banner, Bapu Gaddam, Dharma Rao Polisetti, Robert Carl Andrews, Samuel Victory
  • 4,5-bis(4-bromophenyl)-1-hexyl-2-(4-nitrophenyl)-1H-imidazole as an antimicrobial compound
    Patent number: 11970458
    Abstract: An 4,5-bis(4-bromophenyl)-1-hexyl-2-(4-nitrophenyl)-1H-imidazole compound, its synthesis, and its use as an antimicrobial agent.
    Type: Grant
    Filed: October 27, 2023
    Date of Patent: April 30, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Hany Mohamed Abd El-Lateef Ahmed, Mai Mostafa Khalaf Ali, Antar Ahmed Abdelhamid Ahmed
  • 3-(4,5-bis(4-bromophenyl)-2-(4-chlorophenyl)-1H-imidazol-1-yl)propanoic acid as an antimicrobial compound
    Patent number: 11970459
    Abstract: An 3-(4,5-bis(4-bromophenyl)-2-(4-chlorophenyl)-1H-imidazol-1-yl)propanoic acid compound, its synthesis, and its use as an antimicrobial agent.
    Type: Grant
    Filed: January 29, 2024
    Date of Patent: April 30, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Hany Mohamed Abd El-Lateef Ahmed, Mai Mostafa Khalaf Ali, Antar Ahmed Abdelhamid Ahmed, Amer A. Amer
  • 4-(4,5-bis(4-bromophenyl)-2-phenyl-1H-imidazol-1-yl)benzoic acid as an antimicrobial compound
    Patent number: 11970460
    Abstract: A 4-(4,5-bis(4-bromophenyl)-2-phenyl-1H-imidazol-1-yl)benzoic acid compound, its synthesis, and its use as an antimicrobial agent.
    Type: Grant
    Filed: October 24, 2023
    Date of Patent: April 30, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Hany Mohamed Abd El-Lateef Ahmed, Mai Mostafa Khalaf Ali, Antar Ahmed Abdelhamid Ahmed, Amer A. Amer
  • 1-hexyl-5-(4-methoxyphenyl)-2,4-diphenyl-1H-imidazole as an antimicrobial compound
    Patent number: 11970461
    Abstract: A 1-hexyl-5-(4-methoxyphenyl)-2,4-diphenyl-1H-imidazole compound, its synthesis, and its use as an antimicrobial agent.
    Type: Grant
    Filed: December 14, 2023
    Date of Patent: April 30, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Hany Mohamed Abd El-Lateef Ahmed, Mai Mostafa Khalaf Ali, Antar Ahmed Abdelhamid Ahmed
  • Ethyl 3-[4,4-bis(4-chlorophenyl)-2,5-dioxoimidazolidin-1-yl]propanoate as an antimicrobial compound
    Patent number: 11970462
    Abstract: An ethyl 3-[4,4-bis(4-chlorophenyl)-2,5-dioxoimidazolidin-1-yl]propanoate compound, its synthesis, and its use as an antimicrobial agent.
    Type: Grant
    Filed: January 3, 2024
    Date of Patent: April 30, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Mai Mostafa Khalaf Ali, Mohamed Gouda, Hany Mohamed Abd El-Lateef Ahmed, Tamer Mohamed Abdelghani Ibrahim, Antar Ahmed Abdelhamid Ahmed
  • Compounds and their use
    Patent number: 11970463
    Abstract: The specification generally relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof, where R1, R2A, R2B, R2C, R2D, W, X, Y, and Z have the meanings defined herein. Such compounds are useful in inhibiting NLRP3 inflammasome activity and may be useful as therapeutic agents. The specification also relates to the use of such compounds to treat or prevent diseases and conditions in which the NLRP3 inflammasome is implicated. The specification further relates to compositions comprising such compounds.
    Type: Grant
    Filed: July 1, 2022
    Date of Patent: April 30, 2024
    Assignees: AstraZeneca AB, Mitsubishi Tanabe Pharma Corporation
    Inventors: Lars Anders Mikael Johansson, Giulia Bergonzini, Henrik Gradén, Hiroshi Sugama, Takehiko Matsumura
  • Multi-target drug candidates for the treatment of triple-negative breast cancer
    Patent number: 11970464
    Abstract: Multitarget-directed compounds combining the features of reactive oxygen species (ROS) modulators, poly (ADP-ribose) polymerase 1 (PARP1), and/or heat shock protein 90 (Hsp90) inhibitors in a single molecule. These single agents constitute a systemic regimen for treating the triple-negative breast cancer phenotype that overcomes drug resistance and tumor recurrence, and may be used for other indications as well, such as the treatment of various neurodegenerative disorders.
    Type: Grant
    Filed: November 1, 2023
    Date of Patent: April 30, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Saad Shaaban, Hany Mohamed Abd El-Lateef Ahmed, Bander Alshemary
  • Ethyl {[4-benzoyl-5-(3-fluorophenyl)-4H-1,2,4-triazol-3-yl]thio}acetate as an antimicrobial compound
    Patent number: 11970465
    Abstract: An ethyl {[4-benzoyl-5-(3-fluorophenyl)-4H-1,2,4-triazol-3-yl]thio}acetate compound, its synthesis, and its use as an antimicrobial agent.
    Type: Grant
    Filed: October 17, 2023
    Date of Patent: April 30, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Hany Mohamed Abd El-Lateef Ahmed, Mai Mostafa Khalaf Ali, Antar Ahmed Abdelhamid Ahmed, Amer A. Amer
  • 4-((5-(3-fluorophenyl)-4-phenyl-4H-1,2,4-triazol-3-ylthio)methyl)benzoic acid as an antimicrobial compound
    Patent number: 11970466
    Abstract: A 4-((5-(3-fluorophenyl)-4-phenyl-4H-1,2,4-triazol-3-ylthio)methyl)benzoic acid compound, its synthesis, and its use as an antimicrobial agent.
    Type: Grant
    Filed: October 25, 2023
    Date of Patent: April 30, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Hany Mohamed Abd El-Lateef Ahmed, Mai Mostafa Khalaf Ali, Antar Ahmed Abdelhamid Ahmed, Amer A. Amer
  • N?-(2-naphthoyloxy)-2-(benzo[d]oxazol-2-yl)acetimidamide as an antimicrobial compound
    Patent number: 11970467
    Abstract: A N?-(2-naphthoyloxy)-2-(benzo[d]oxazol-2-yl)acetimidamide compound, its synthesis, and its use as an antimicrobial agent.
    Type: Grant
    Filed: October 13, 2023
    Date of Patent: April 30, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Hany Mohamed Abd El-Lateef Ahmed, Mai Mostafa Khalaf Ali, Antar Ahmed Abdelhamid Ahmed, Amer A. Amer
  • 2-(benzo[d]oxazol-2-yl)-N?-(3,5-dichlorobenzoyloxy)acetimidamide as an antimicrobial compound
    Patent number: 11970468
    Abstract: A 2-(benzo[d]oxazol-2-yl)-N?-(3,5-dichlorobenzoyloxy)acetimidamide compound, its synthesis, and its use as an antimicrobial agent.
    Type: Grant
    Filed: October 23, 2023
    Date of Patent: April 30, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Hany Mohamed Abd El-Lateef Ahmed, Mai Mostafa Khalaf Ali, Antar Ahmed Abdelhamid Ahmed, Amer A. Amer
  • Compounds useful in the treatment of disorders associated with mutant RAS
    Patent number: 11970469
    Abstract: The present invention relates to compounds of Formula I as defined herein, and salts and solvates thereof. (I) The present invention also relates to pharmaceutical compositions comprising compounds of Formula (I), and to compounds of Formula (I) for use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which inhibition of a RAS-effector protein-protein interaction is implicated.
    Type: Grant
    Filed: June 3, 2019
    Date of Patent: April 30, 2024
    Assignee: THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL
    Inventors: Terrence Rabbitts, Camilo Quevedo, Carole Bataille
  • {5-chloro-2-(2-(3-(substitutedphenyl)-1,2,4-oxadiazol-5-yl)ethyl)phenyl}(phenyl)methanones as larvicidal agents
    Patent number: 11970470
    Abstract: Compounds for treating preventing malaria and, particularly, to larvicidal agents that are {5-chloro-2-(2-(3-(substitutedphenyl)-1,2,4-oxadiazol-5-yl)ethyl)phenyl}(phenyl)methanones derivatives and their use as larvicidal agents.
    Type: Grant
    Filed: November 10, 2023
    Date of Patent: April 30, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Katharigatta N. Venugopala, Pran Kishore Deb, Rashmi Venugopala
  • 3-(4-chlorophenyl)-5-{[5-methyl-2-(propan-2-yl)phenoxy]methyl }- 1,2,4-oxadiazole as an antitumor and antimicrobial compound
    Patent number: 11970471
    Abstract: A compound 3-(4-chlorophenyl)-5-{[5-methyl-2-(propan-2-yl)phenoxy]methyl}-1,2,4-oxadiazole compound, its synthesis, and its use as an anticancer and/or antimicrobial agent.
    Type: Grant
    Filed: December 26, 2023
    Date of Patent: April 30, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Mai Mostafa Khalaf Ali, Hany Mohamed Abd El-Lateef Ahmed, Antar Ahmed Abdelhamid Ahmed, Amer A. Amer, Sahar M. Mohamed, Mohammad Mahboob Alam
  • 5-((2-isopropyl-5-methylphenoxy)methyl)-3-(naphthalen-1-yl)-1,2,4-oxadiazole as an anti-cancer and antimicrobial compound
    Patent number: 11970472
    Abstract: A 5-((2-isopropyl-5-methylphenoxy)methyl)-3-(naphthalen-1-yl)-1,2,4-oxadiazole compound, its synthesis, and its use as an antimicrobial agent.
    Type: Grant
    Filed: November 2, 2023
    Date of Patent: April 30, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Hany Mohamed Abd El-Lateef Ahmed, Mai Mostafa Khalaf Ali, Antar Ahmed Abdelhamid Ahmed, Amer A. Amer
  • Nootkatone derivatives and methods of using the same
    Patent number: 11970473
    Abstract: Nootkatone derivatives comprising a fused thiazole ring and methods of using the same are disclosed herein.
    Type: Grant
    Filed: March 31, 2022
    Date of Patent: April 30, 2024
    Assignee: Arkansas State University—Jonesboro
    Inventor: Mohammad Abrar Alam
  • Substituted benzodiazoles and use thereof in therapy
    Patent number: 11970474
    Abstract: There is provided herein a compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein R1, R2, X1, X2, Y1 to Y4, Z1 to Z3 and n have meanings provided in the description.
    Type: Grant
    Filed: March 1, 2019
    Date of Patent: April 30, 2024
    Assignee: THOMAS HELLEDAYS STIFTELSE FÖR MEDICINSK FORSKNING
    Inventors: Armando Cázares-Körner, Thomas Helleday, Torkild Visnes, Olov Wallner, Tobias Koolmeister
  • 4-(1-(2-Hydroxypropyl)-4,5-diphenyl-1H-imidazol-2-yl)pyridin-3-ol as an antimicrobial compound
    Patent number: 11970475
    Abstract: A 4-(1-(2-Hydroxypropyl)-4,5-diphenyl-1H-imidazol-2-yl)pyridin-3-ol compound, its synthesis, and its use as an antimicrobial agent.
    Type: Grant
    Filed: September 5, 2023
    Date of Patent: April 30, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Mai Mostafa Khalaf Ali, Hany Mohamed Abd El-Lateef Ahmed, Antar Ahmed Abdelhamid Ahmed, Adel A. Marzouk
  • 6?-(4-chlorophenyl)-2?-alkoxy-3,4?-bipyridine-3?-carbonitriles as antimicrobial compounds
    Patent number: 11970476
    Abstract: A 6?-(4-chlorophenyl)-2?-alkoxy-3,4?-bipyridine-3?-carbonitrile compound, its synthesis, and its use as an antimicrobial agent.
    Type: Grant
    Filed: October 11, 2023
    Date of Patent: April 30, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Mai Mostafa Khalaf Ali, Hany Mohamed Abd El-Lateef Ahmed, Antar Ahmed Abdelhamid Ahmed, Amer A. Amer
  • 9-(2-hydroxyquinoline-3-yl)-10-[3-(dimethylamino)propyl]-3,4,6,7,9,10-hexahydroacridine-1,8(2H,5H)-dione as an antimicrobial compound
    Patent number: 11970477
    Abstract: An 9-(2-hydroxyquinoline-3-yl)-10-[3-(dimethylamino)propyl]-3,4,6,7,9,10-hexahydroacridine-1,8(2H,5H)-dione compound, its synthesis, and its use as an antimicrobial agent.
    Type: Grant
    Filed: November 3, 2023
    Date of Patent: April 30, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Hany Mohamed Abd El-Lateef Ahmed, Mai Mostafa Khalaf Ali, Antar Ahmed Abdelhamid Ahmed
  • 9-(2-hydroxyquinolin-3-yl)-10-(2-hydroxyethyl)-3,3,6,6-tetramethyl-3,4,6,7,9,10-hexahydroacridine1,8(2H,5H)-dione as an antimicrobial compound
    Patent number: 11970478
    Abstract: A 9-(2-hydroxyquinolin-3-yl)-10-(2-hydroxyethyl)-3,3,6,6-tetramethyl-3,4,6,7,9,10-hexahydroacridine1,8(2H,5H)-dione compound, its synthesis, and its use as an antimicrobial agent.
    Type: Grant
    Filed: November 16, 2023
    Date of Patent: April 30, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Hany Mohamed Abd El-Lateef Ahmed, Mai Mostafa Khalaf Ali, Antar Ahmed Abdelhamid Ahmed, Amer A. Amer
  • 3-(1H-pyrazol-4-yl)pyridine allosteric modulators of the M4 muscarinic acetylcholine receptor
    Patent number: 11970479
    Abstract: The present invention is directed to cinnolinyl and quinolinyl pyrazol-4-yl-pyridine compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M4 muscarinic acetylcholine receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M4 muscarinic acetylcholine receptors are involved.
    Type: Grant
    Filed: October 24, 2019
    Date of Patent: April 30, 2024
    Assignees: Merck Sharp & Dohme LLC, MSD R&D (China) Co. LTD.
    Inventors: John J. Acton, III, Melissa Egbertson, Xiaolei Gao, Scott T. Harrison, Timothy J. Henderson, Michael Man-Chu Lo, Robert D. Mazzola, Jr., Zhaoyang Meng, James Mulhearn, Vanessa L. Rada, Jeffrey W. Schubert, Oleg B. Selyutin, David M. Tellers, Ling Tong, Fengqi Zhang, Jianming Bao, Chunsing Li
  • Heterocyclic amides useful as protein modulators
    Patent number: 11970480
    Abstract: Disclosed are compounds having the formula: wherein q, r, s, A, B, C, RA1, RA2, RB1, RB2, RC1, RC2, R3, R4, R5, R6, R14, R15, R16, and R17, are as defined herein, or a tautomer thereof, or a salt, particularly a pharmaceutically acceptable salt, thereof.
    Type: Grant
    Filed: May 17, 2022
    Date of Patent: April 30, 2024
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Adam Kenneth Charnley, Michael G. Darcy, Jason W. Dodson, Xiaoyang Dong, Terry V. Hughes, Jianxing Kang, Lara Kathryn Leister, Yiqian Lian, Yue Li, John F. Mehlmann, Neysa Nevins, Joshi M. Ramanjulu, Joseph J. Romano, Gren Z. Wang, Guosen Ye, Daohua Zhang
  • Substituted pyridine derivatives as SARM1 inhibitors
    Patent number: 11970481
    Abstract: This disclosure is drawn to substituted pyridine compounds and compositions, and associated methods, useful for inhibition of SARM1 activity and/or for treating or preventing a neurological diseases.
    Type: Grant
    Filed: October 4, 2023
    Date of Patent: April 30, 2024
    Assignee: NURA BIO, INC.
    Inventors: Jennifer Aiden Kozak, Sean Pomeroy Brown, Christopher Michael Tegley, Alexander Wayne Schammel, Liusheng Zhu, Maximiliano De La Higuera Macias, Shilpa Sambashivan
  • Acetal compounds and therapeutic uses thereof
    Patent number: 11970482
    Abstract: Disclosed herein are acetal and cyclic acetal compounds, compositions, their preparation, and their uses. Some embodiments relate to their use as liver-targeting compounds.
    Type: Grant
    Filed: January 8, 2019
    Date of Patent: April 30, 2024
    Assignee: LIGAND PHARMACEUTICALS INC.
    Inventor: Lin Zhi
  • Heterocyclic compound
    Patent number: 11970483
    Abstract: The present invention aims to provide a compound that may be useful for the prophylaxis or treatment of constipation and the like. The present invention provides a compound represented by the formula (I): wherein R1 is a hydrogen atom, a halogen atom, an optionally substituted C1-6 alkyl group, or an optionally substituted C1-6 alkoxy group; and ring A is an optionally further substituted ring, or a salt thereof.
    Type: Grant
    Filed: September 27, 2019
    Date of Patent: April 30, 2024
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Shinobu Sasaki, Yasutomi Asano, Kazuaki Takami, Masaki Seto, Haruhi Ando
  • LXR modulators with bicyclic core moiety
    Patent number: 11970484
    Abstract: The present invention relates to bicyclic compounds (e.g. indoles) containing a sulfonyl moiety, which bind to the liver X receptor (LXR? and/or LXK?) and act preferably as inverse agonists of LXR.
    Type: Grant
    Filed: February 9, 2023
    Date of Patent: April 30, 2024
    Assignee: OrsoBio, Inc.
    Inventors: Christian Gege, Olaf Kinzel, Eva Hambruch, Manfred Birkel, Claus Kremoser, Ulrich Deuschle
  • RET kinase inhibitors
    Patent number: 11970485
    Abstract: Disclosed herein are compounds of formula I: or a pharmaceutically acceptable salt thereof, where the variables are as defined herein. These compounds are useful in treating RET associated cancers. Formulations containing the compounds of formula I and methods of making the compounds of formula I are also disclosed.
    Type: Grant
    Filed: October 19, 2022
    Date of Patent: April 30, 2024
    Assignee: ELI LILLY AND COMPANY
    Inventors: Gabrielle R. Kolakowski, Erin D. Anderson, Steven W. Andrews, Christopher Pierre Albert Jean Boldron, Kevin R. Condroski, Thomas C. Irvin, Manoj Kumar, Elizabeth A. McFaddin, Megan L. McKenney, Johnathan Alexander McLean, Tiphaine Mouret, Michael J. Munchhof, Thomas Pierre Dino Pancaldi, Michael Alexander Pilkington-Miksa, Marta Pinto
  • Compounds and uses thereof
    Patent number: 11970486
    Abstract: The present invention features compounds useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders.
    Type: Grant
    Filed: October 24, 2017
    Date of Patent: April 30, 2024
    Assignee: Janssen Pharmaceutica NV
    Inventors: Bertrand Le Bourdonnec, Matthew Lucas, Kerem Ozboya, Bhaumik Pandya, Parcharee Tivitmahaisoon, Iwona Wrona
  • 7-(4-((5-(benzylideneamino)-2-thioxo-1,3,4-thiadiazol-3(2h)-yl)methyl)piperazin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid as an anti-inflammatory and anticancer compound
    Patent number: 11970487
    Abstract: A 7-(4-((5-(benzylideneamino)-2-thioxo-1,3,4-thiadiazol-3(2H)-yl)methyl)piperazin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid compound, its synthesis, and its use as an anticancer and/or anti-inflammatory agent, and having the formula:
    Type: Grant
    Filed: September 1, 2023
    Date of Patent: April 30, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Hany Mohamed Abd El-Lateef Ahmed, Mai Mostafa Khalaf Ali, Antar Ahmed Abdelhamid Ahmed, Amer A. Amer
  • 2-(benzo[d]thiazol-2-yl)-N'-(2-(5-phenyl-1,3,4-oxadiazol-2-ylthio)acetoxy)acetimidamide as an antimicrobial compound
    Patent number: 11970488
    Abstract: A 2-(benzo[d]thiazol-2-yl)-N?-(2-(5-phenyl-1,3,4-oxadiazol-2-ylthio)acetoxy)acetimidamide compound, its synthesis, and its use as an antimicrobial agent.
    Type: Grant
    Filed: October 13, 2023
    Date of Patent: April 30, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Hany Mohamed Abd El-Lateef Ahmed, Mai Mostafa Khalaf Ali, Antar Ahmed Abdelhamid Ahmed, Amer A. Amer
  • 4-[(substituted 1H-benzimidazol-2-ylsulfanyl)methyl]-6-substituted-2H-chromen-2-ones as larvicidal agents
    Patent number: 11970489
    Abstract: Compounds for treating preventing malaria and, particularly, to larvicidal agents that are 4-[(substituted 1H-benzimidazol-2-ylsulfanyl)methyl]-6-substituted-2H-chromen-2-ones derivatives and their use as larvicidal agents.
    Type: Grant
    Filed: October 23, 2023
    Date of Patent: April 30, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Katharigatta N. Venugopala, Osama I. Alwassil, Pran Kishore Deb, Rashmi Venugopala, Priya R. Kadam, Yadav D. Bodke, Vijaykumar Uppar
  • Stable heavy isotopes in amide functional groups and uses thereof
    Patent number: 11970490
    Abstract: There are provided isotope-enriched compounds containing stable heavy isotope-enriched amide functional groups for modulating the pharmacokinetic profile, metabolic profile, and/or delivery efficiency of a drug or prodrug, as well as its therapeutic or prophylactic efficacy and/or adverse effects. Use of the isotope-enriched amide-containing drugs and prodrugs for the treatment or prevention of disease states and conditions is also provided.
    Type: Grant
    Filed: March 25, 2021
    Date of Patent: April 30, 2024
    Assignees: RISEN (SUZHOU) PHARMA TECH CO., LTD., SHANGHAI JUNSHI BIOSCIENCES CO., LTD.
    Inventors: Jiasheng Lu, Jiamin Gu, Xiang Ji, Dongqing Zhu, Xiaolin He, Xianqi Kong
  • N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amine derivatives as therapeutic compounds
    Patent number: 11970491
    Abstract: A novel class of inhibitors of protein kinates that are useful in the treatment of cell proliferative diseases and conditions, and especially those characterised by over-expression of CDK4, CDK6 and/or cyclin D, including certain cancers of lung, breast, brain, central nervous system, colorectal cancer and leukaemias.
    Type: Grant
    Filed: August 31, 2021
    Date of Patent: April 30, 2024
    Assignee: AUCENTRA THERAPEUTICS PTY LTD
    Inventors: Shudong Wang, Solomon Tadesse Zeleke, Mingfeng Yu
  • 11-arylcinnolino[2,3-f]phenanthridinium salts and method for producing the same
    Patent number: 11970492
    Abstract: The present invention provides 11-arylcinnolino[2,3-f]phenanthridinium salt compounds and method for producing the same by highly regioselective synthesis of 11-phenylimino[2,3-f]phenanthridin-9-ium salts from 2-azobiaryls and alkenes under catalysis of palladium, through double oxidative C—H coupling of alkenes, to give the polycyclic cinnolinophenanthridinium salts in moderate yields. The reaction mechanism involves ortho C—H olefination of 2-azobiaryls by alkenes, intramolecular aza-Michael addition, ?-hydride elimination, electrophilic palladation followed by intramolecular C—H activation and reductive elimination. The prepared quaternary ammonium salts are candidate materials for solution-processable OLED and bioimaging materials.
    Type: Grant
    Filed: January 29, 2021
    Date of Patent: April 30, 2024
    Assignee: NATIONAL CHIAO TUNG UNIVERSITY
    Inventors: Shih-Ching Chuang, Jayakumar Jayachandran
  • Autotaxin inhibitor compounds
    Patent number: 11970493
    Abstract: The present disclosure provides autotaxin (ATX) inhibitor compounds and compositions including said compounds. The present disclosure also provides methods of using said compounds and compositions for inhibiting ATX. Also provided are methods of preparing said compounds and compositions, and synthetic precursors of said compounds.
    Type: Grant
    Filed: October 4, 2021
    Date of Patent: April 30, 2024
    Assignee: ILDONG PHARMACEUTICAL CO., LTD.
    Inventors: Sung-Ku Choi, Yoon-Suk Lee, Sung-Wook Kwon, Kyung-Sun Kim, Jeong-Geun Kim, Jeong-Ah Kim, An-Na Moon, Sun-Young Park, Jun-Su Ban, Dong-Keun Song, Kyu-Sic Jang, Ju-Young Jung, Soo-Jin Lee
  • 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors
    Patent number: 11970494
    Abstract: The present disclosure provides 6-heteroaryloxy benzimidazole and azabenzimidazole compounds and compositions thereof useful for inhibiting JAK2.
    Type: Grant
    Filed: November 8, 2022
    Date of Patent: April 30, 2024
    Assignee: Ajax Therapeutics, Inc.
    Inventors: Craig E. Masse, Jeremy R. Greenwood, Jiayi Xu, Sayan Mondal, Phani Ghanakota
  • Indolizine derivatives and their application in medicine
    Patent number: 11970495
    Abstract: This invention relates to indolizine derivatives and their use in medicine. In particular, the present invention discloses novel substituted indolizine derivatives of formula I, or an isotopically labeled compound thereof, or an optical isomer thereof, a geometric isomer thereof, a tautomer thereof or a mixture of various isomers, or a pharmaceutically acceptable salt thereof, or a prodrug thereof. The invention also relates to the use of these compounds in medicine.
    Type: Grant
    Filed: April 10, 2023
    Date of Patent: April 30, 2024
    Assignee: KIND PHARMACEUTICAL
    Inventors: Dong Liu, Dongdong Chen, Biao Deng, Xiangyun Tu, Zinan Fang, Haohao Wu, Danyan Gu
  • Pyrrolo[3,2-c]quinoline compounds as CK2 inhibitors
    Patent number: 11970496
    Abstract: Novel pyrrolo[3,2-c]quinoline compounds, a method of synthesizing these compounds, a pharmaceutical composition comprising these compounds and a suitable carrier, and a method of using the compounds. The pyrrolo[3,2-c]quinoline compounds, identified as CK2 inhibitors, have the following formula I with the substituents as defined in the instant specification, and are useful as anticancer and/or antitumor agents, and as agents for treating other kinase associated conditions including inflammation, pain, and certain immunological disorders, and other types of diseases such as diabetes, viral infection, neurodegenerative diseases.
    Type: Grant
    Filed: December 7, 2023
    Date of Patent: April 30, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Michelyne Haroun, Christophe Tratrat
  • Tricyclic AKR1C3 dependent KARS inhibitors
    Patent number: 11970497
    Abstract: The present invention relates to novel tricyclic compounds that are AKR1C3 dependent KARS inhibitor, processes for their preparation, pharmaceutical compositions, and medicaments containing them, and their use in diseases and disorders mediated by an AKR1C3 dependent KARS inhibitor.
    Type: Grant
    Filed: July 31, 2020
    Date of Patent: April 30, 2024
    Assignee: Novartis AG
    Inventors: Chris Adair, Tracy Chen, Jian Ding, Christy Fryer, Yuko Isome, Marie-Helene Larraufie, Katsumasa Nakajima, Nik Savage, Ariel Sterling Twomey
  • CDK2 inhibitors
    Patent number: 11970498
    Abstract: The present disclosure provides a compound represented by structural Formula (I): or a pharmaceutically acceptable salt thereof useful for treating a cancer.
    Type: Grant
    Filed: February 8, 2023
    Date of Patent: April 30, 2024
    Assignee: BLUEPRINT MEDICINES CORPORATION
    Inventors: Douglas Wilson, Neil Bifulco, Jr., Natasja Brooijmans, Joseph L. Kim, Philip D. Ramsden, Richard Vargas, Steven Mark Wenglowsky
  • Pyrazolo[1,5-c]pyrimidine compounds as CK2 inhibitors
    Patent number: 11970499
    Abstract: Novel pyrazolo[1,5-c]pyrimidine compounds, a method of synthesizing said compounds, a pharmaceutical composition comprising said compounds and a suitable carrier, and a method of using the compounds. The pyrazolo[1,5-c]pyrimidine compounds, identified as CK2 inhibitors, are useful as anticancer and/or antitumor agents, and as agents for treating other kinase-associated conditions including inflammation, pain, and certain immunological disorders, and other types of diseases such as diabetes, viral infection, neurodegenerative diseases.
    Type: Grant
    Filed: December 22, 2023
    Date of Patent: April 30, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Michelyne Haroun, Christophe Tratrat
  • Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)- 2-(4-phenoxyphenyl)-4,5,6,7-tetra- hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
    Patent number: 11970500
    Abstract: The present invention relates to a crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetr a-hydropyrazolo[1,5-a]pyrimi dine-3-carboxamide for inhibiting Btk, methods of preparation thereof and pharmaceutical compositions, and use of the crystalline form above in the treatment of a disease, or in the manufacturing of a medicament for the treatment of a disease.
    Type: Grant
    Filed: December 1, 2023
    Date of Patent: April 30, 2024
    Assignee: BeiGene Switzerland GmbH
    Inventors: Zhiwei Wang, Yunhang Guo, Gongyin Shi, Lai Wang
  • Highly polarizable 3D organic perovskites and electro-optic materials comprising same
    Patent number: 11970501
    Abstract: The present invention relates to highly polarizable 3D organic perovskites of the general formula ABX3, prepared by introducing halogen functional groups in the A-site cation (in which the A and B sites are occupied by organic cations and the X site is a monovalent non-metallic counterion). The (DCl)(NH4)(BF4)3 crystal exhibits a strong linear electrooptic (EO) effect with an effective EO coefficient of 20 pmV?1, which is 10 times higher than that of metal halide perovskites. These 3D organic perovskites are solution processed and compatible with silicon, and illustrate the potential of rationally-designed all-organic perovskites for use in on-chip modulators, electro-optic devices, piezoelectric devices, or silicon photonics devices.
    Type: Grant
    Filed: September 1, 2021
    Date of Patent: April 30, 2024
    Assignee: HUAWEI TECHNOLOGIES CANADA CO., LTD.
    Inventors: Meng-Jia Sun, Chao Zheng, Sjoerd Hoogland, Edward Hartley Sargent
  • Macrocyclic antiviral agents
    Patent number: 11970502
    Abstract: The present invention discloses macrocyclic compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: May 3, 2022
    Date of Patent: April 30, 2024
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Jiajun Zhang, Xiaowen Peng, Yat Sun Or
  • Radiopharmaceuticals, radioimaging agents, and uses thereof
    Patent number: 11970503
    Abstract: The present invention relates to compounds that are useful as radiopharmaceuticals and radioimaging agents which bear a radionuclide-chelating agent. These coordinated compounds are useful in radiotherapy and diagnostic imaging. The invention also relates to methods of diagnosis, prognosis and therapy utilising the non-coordinated and radiolabelled compounds of the invention.
    Type: Grant
    Filed: June 7, 2022
    Date of Patent: April 30, 2024
    Assignee: Clarity Pharmaceuticals Ltd
    Inventors: Nicholas Alan Zia, Paul Stephen Donnelly